LOGIN  |  REGISTER
Astria Therapeutics
Astria Therapeutics

iSpecimen to Participate in Maxim Group Healthcare IT Virtual Conference, January 24 & 25, 2024

January 18, 2024 | Last Trade: US$3.00 0.04 1.35

LEXINGTON, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today that it will be participating in the Maxim Group Virtual Healthcare IT Conference on January 25, 2024. Tracy Curley, Chief Executive Officer, will present at 10:00 a.m. ET.

To access the presentation, please click here.

About iSpecimen

iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.

For further information, please contact:

Investor Contacts
KCSA Strategic Communications
Phil Carlson / Erika Kay
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Media Contacts
KCSA Strategic Communications
Raquel Cona / Shana Marino
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB